Aggressive Non-Hodgkin Lymphoma — Trials

Aggressive Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

648 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 182
Recruiting: 92
Ph III recruiting: 4
Growth YoY: +6.7%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 101–107 of 107 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06635330	Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL	recruiting	Phase 1 / Phase 2	5	Kara Yakhteh Tajhiz Azma CompanyNETWORK	1	Oct 10, 2024	clinicaltrials
NCT06598722	BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.	recruiting	Phase 2	206	Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER	1	Sep 24, 2024